Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals, Inc. will present an abstract on a post-hoc analysis of Amisulpride for PONV at the 77th PGA in NYC. The analysis shows that Barhemsys, an FDA-approved antiemetic, significantly reduces nausea in PONV patients. A unique J-code for Barhemsys will be effective from January 1, 2024.
December 06, 2023 | 9:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eagle Pharmaceuticals' Barhemsys demonstrated significant nausea relief in PONV patients, with a new J-code effective Jan 2024, indicating potential increased usage and sales.
The positive results from the post-hoc analysis of Barhemsys are likely to bolster the drug's credibility and usage among healthcare providers, potentially leading to increased sales. The new J-code effective in 2024 will streamline billing for Barhemsys, further supporting its market adoption.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100